Holen Sie sich die Stockscreener-App
11.10
1.42%
-0.16
Schlusskurs vom Vortag:
$11.26
Offen:
$10.65
24-Stunden-Volumen:
64,467
Relative Volume:
0.16
Marktkapitalisierung:
$1.52B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-102.09M
KGV:
-10.57
EPS:
-1.05
Netto-Cashflow:
$-108.72M
1W Leistung:
+12.92%
1M Leistung:
+40.33%
6M Leistung:
+276.40%
1J Leistung:
+87.82%
1-Tages-Spanne:
$10.47
$11.29
1-Wochen-Bereich:
$10.03
$12.78
52-Wochen-Spanne:
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Vergleichen Sie DBVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
11.10 | 268.88M | 0 | -102.09M | -108.72M | -1.05 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold |
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy |
| 2019-12-16 | Eingeleitet | Citigroup | Buy |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Eingeleitet | Goldman | Buy |
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-03 | Eingeleitet | Barclays | Overweight |
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
DBV Technologies Sets Critical Shareholder Meeting: Key Documents Now Available - Stock Titan
European ADRs Show Modest Gains With Standout Performers - Finimize
StockNews.com Upgrades DBV Technologies (NASDAQ:DBVT) to “Hold” - Defense World
FY2025 EPS Forecast for DBV Technologies Boosted by Analyst - Defense World
European ADRs Dip With Mixed Performances Across Key Sectors - Finimize
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A.DBVT - Barchart.com
HC Wainwright Issues Positive Forecast for DBV Technologies (NASDAQ:DBVT) Stock Price - Defense World
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - The Manila Times
DBV Technologies CEO Set for Key Presentation: How to Watch Live Fireside Chat at JMP Conference - Stock Titan
DBV Technologies stock target raised to $16 by H.C. Wainwright - Investing.com Nigeria
JMP Securities Boosts DBV Technologies (NASDAQ:DBVT) Price Target to $15.00 - Defense World
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
DBV Technologies Reports First Quarter 2025 Financial Results - EIN News
DBV Technologies Secures Massive $306.9M Financing Despite Q1 Losses: Cash Runway Extended - Stock Titan
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Gains Despite Mixed Performances In Key Sectors - Finimize
StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT) - Defense World
Vaxcyte (NASDAQ:PCVX) versus DBV Technologies (NASDAQ:DBVT) Critical Survey - The AM Reporter
DBV Technologies (NASDAQ:DBVT) & Vaxcyte (NASDAQ:PCVX) Critical Contrast - Defense World
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - Informazione.it
DBV Technologies S.A. SEC 10-K Report - TradingView
DBV Technologies Completes Dual-Market Financial Filings for 2024 - Stock Titan
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
European ADRs Show Mixed Fortunes In US Market - Finimize
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com - Defense World
European ADRs See Mixed Results With Biopharma Leading Gains - Finimize
Why DBV Technologies (DBVT) Stock Is Skyrocketing - Benzinga
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' - Benzinga
DBV Technologies announces up to $307M financing to advance Viaskin Peanut program - MSN
DBV Technologies Announces Financing of up to $306.9 - GlobeNewswire
Major Breakthrough: $306.9M Funding Powers Revolutionary Peanut Allergy Patch to FDA Finish Line - Stock Titan
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):